Inherited metabolic disease

Current Opinion in Gastroenterology

Volumn 16, Issue 3, 2000, Pages 219-230

  Schilsky, Michael L ^a,c   Mistry, Pramod ^b  

^a Recanati/Miller Transplantation Institute   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c Box 1633 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; GLUCOSYLCERAMIDASE; IMIGLUCERASE; PENICILLAMINE; TRIENTINE; ZINC DERIVATIVE;

CLINICAL TRIAL; ENZYME REPLACEMENT; GAUCHER DISEASE; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; HEMOCHROMATOSIS; HUMAN; LIVER TOXICITY; METAL METABOLISM; NEUROTOXICITY; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; REVIEW; WILSON DISEASE;

EID: 0034465005     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200005000-00004     Document Type: Review

References (63)

1. Penicillamine: The treatment of first choice for patients with Wilson's disease
2. Penicillamine should not be used as initial therapy in Wilson's disease
3. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy
4. Potential hepatotoxicity of penicillamine treatment in three patients with Wilson's disease
5. Liver transplantation for Wilson's disease: A single-center experience
6. Auxiliary partial orthotopic living donor liver transplantation as an aid for small-for-size grafts in larger recipients
7. A study of Wilson disease mutations in Britain
8. The His1069GIn mutation in the ATP7B gene in Russian patients with Wilson disease
9. Hepatocyte-specific localization and copper-dependent trafficking of the Wilson's disease protein in the liver
10. Localization of the Wilson's disease protein in human liver
11. Two forms of Wilson's disease protein in different subcellular fractions of normal liver
12. Wilson's disease gene product ATP7B localizes in the late endosomes in a human hepatoma cell line and normal rat hepatocytes: Participation in biliary copper excretion
13. A delicate balance: Homeostatic control of copper uptake and distribution
14. Role of the copper-binding domain in the copper transport function of ATP7B, the P-type ATPase defective in Wilson disease
15. Biliary excretion of copper in LEC rat after introduction of copper transporting P-type ATPase, ATP7B
16. Liver repopulation with hepatocyte transplantation corrects abnormal copper metabolism and eliminates copper toxicosis in the LEC rat, a model of Wilson's disease
17. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux
18. Hephaestin, a ceruloplasmin homologue implicated in intestinal irion transport, is defective in the sla mouse
19. Population screening for hemochromatosis
20. A population-based study of the clinical expression of the hemochromatosis gene
21. HFE genotype in patients with hemochromatosis and other liver diseases
22. Clinical implications of the hemochromatosis gene
23. Phenotypic expression of HFE mutations: A French study of 1110 unrelated iron-overloaded patients and relatives
24. Insulin resistance-associated hepatic iron overload
25. Hereditary hemochromatosis in liver transplantation
26. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in hemochromatosis
27. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote
28. Two novel missense mutations of the HFE gene (1105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands
29. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene
30. Prevalence of the C282Y mutation of the hemochromatosis gene in liver transplant recipients and donors
31. The haemochromatosis gene: A co-factor for chronic liver diseases?
32. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
33. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women
34. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation
35. Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report
36. P53 mutations in British patients with hepatocellular carcimona: Clustering in genetic hemochromatosis
37. The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells
38. Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces an iron-deficient phenotype
39. HFE downregulates iron uptake from transferrin and induces iron-regulatory protein activity in stably transfected cells
40. Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: Implications for cellular iron homeostasis
41. Alternate splicing produces a soluble form of the hereditary hemochromatosis protein HFE
42. Distribution of HFE protein in rat small intestine
43. Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum
44. Duodenal metal transporter (DMT-1, NRAMP-2) expression in patients with hereditary hemochromatosis
45. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: Increased duodenal expression of the iron transporter DMT1
46. The iron transport protein NRAMP2 is an integral membrane glycoprotein that colocalizes with transferrin in recycling endosomes
47. Intracellular transport of acid β glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R) mutation
48. Non-pseudogene-derived acid β glucosidase mutations causing mild type 1 and severe type 2 Gaucher disease
49. Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation
50. Type 2 Gaucher disease: An expanding phenotype
51. Delivery, distribution and neuronal uptake of exogenous mannose-terminated glucocerebrosidase in the intact rat brain
52. Pulmonary pathology in Gaucher disease
53. Echocardiographic assessment of pulmonary hypertension in Gaucher disease
54. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher disease
55. Pulmonary hypertension after splenectomy
56. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humeral tolerance in seroconverted patients after repeat administration
57. A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: Implications for clinical efficacy in treatment of Gaucher disease
58. Treatment of Gaucher disease with an enzyme inhibitor
59. New therapeutic prospects for the glycospair golipid lysosomal storage diseases
60. Prevention of lysosomal storage in Tay-Sachs mice treated with N-Butyldeoxynojirimicin
61. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimicin
62. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder
63. Accelerated transport and maturation of lysosomal α galactosidase A in Fabry lymphoblasts by an enzyme inhibitor